Company: TELO
Filing Date: 2025-02-14
Form Type: S-3
Source: 0001493152-25-006943
Chunk: 43

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-14
Form: S-3
Chunk 43
---
 this offering. We currently intend to use the net proceeds from the sale of securities offered by this prospectus, if any, for general corporate purposes, including the advancement of our drug candidates in clinical trials, regulatory submissions, potential commercial activity, preclinical research and development, capital expenditures, and to meet working capital needs.

Investors are cautioned, however, that expenditures may vary substantially from these uses. Investors will be relying on the judgment of our management, who will have broad discretion regarding the application of the proceeds of this offering. The amounts and timing of our actual expenditures will depend upon numerous factors, including the amount of cash generated by our operations, the amount of competition and other operational factors. We may find it necessary or advisable to use portions of the proceeds from this offering for other purposes.

From time to time, we evaluate these and other factors and we anticipate continuing to make such evaluations to determine if the existing allocation of resources, including the proceeds of this offering, is being optimized. Circumstances that may give rise to a change in the use of proceeds include:

| ● | a change in development plan                            
 or strategy;                                            |
| ● | the addition of new products                            
 or applications;                                        |
| ● | technical delays;                                       |
| ● | delays or difficulties with                             
 our clinical trials;                                    |
| ● | negative results from our                               
 clinical trials;                                        |
| ● | difficulty obtaining FDA                                
 approval; and                                           |
| ● | the availability of other                               
 sources of cash including additional offerings, if any. |

Pending other uses, we intend to invest the proceeds to us in investment-grade, interest-bearing securities such as money market funds, certificates of deposit, or direct or guaranteed obligations of the U.S. government, or hold as cash. We cannot predict whether the proceeds invested will yield a favorable, or any, return.

| Alt-13 |

<div align='center'>DILUTION</div>

If you invest in our common stock, your interest will be diluted to the extent of the difference between the price per share you pay in this offering and the net tangible book value per share of common stock immediately after this offering. The net tangible book value of our common stock as of December 31, 2024, was approximately $0.65 million, or approximately $0.02 per share of common stock based on 29,762,671 shares of common stock outstanding on that date. “Net tangible book value” is total assets minus the sum of liabilities and intangible assets. “Net tangible book value